ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AXNX Axonics Inc

67.40
0.08 (0.12%)
After Hours
Last Updated: 22:59:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Axonics Inc NASDAQ:AXNX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.08 0.12% 67.40 65.77 68.73 67.49 67.19 67.40 223,970 22:59:01

Axonics to Participate in November Investor Conferences

01/11/2023 10:00am

Business Wire


Axonics (NASDAQ:AXNX)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Axonics Charts.

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November:

Event: Wolfe Research Healthcare Conference Date: Tuesday, November 14 Presentation time: 12:30 p.m. Eastern Time

Event: Piper Sandler Healthcare Conference Date: Wednesday, November 29 Presentation time: 10:30 a.m. Eastern Time

Interested parties may access a live webcast and replay of each presentation by visiting the Axonics investor relations website.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.

Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.

Axonics contact: Neil Bhalodkar 949-336-5293 IR@axonics.com

1 Year Axonics Chart

1 Year Axonics Chart

1 Month Axonics Chart

1 Month Axonics Chart

Your Recent History

Delayed Upgrade Clock